Recently, the first working meeting of the MAH Service and Collaboration Professional Committee of China Pharmaceutical Enterprise Management Association was successfully held in Qilu Pharmaceutical Group, attended by Wang Xuegong, executive vice president of China Pharmaceutical Enterprise Management Association, Tan Yong, vice president, Liu Yu, executive deputy director of the Drug Marketing Licensor Service and Collaboration Committee, and Zhang Hanchang, vice president of Qilu Pharmaceutical Group and general manager of Qilu Pharmaceutical Co., Ltd., which was presided over by Tan Yong.
At the meeting, Liu Yu elaborated on the "2022 Work Plan of the Drug Marketing Licensor Service and Collaboration Committee of the China Pharmaceutical Enterprise Management Association". He said that the special committee should further optimize the organizational structure and effectively carry out key tasks such as brand building, project research, blue book formulation, expert database construction and organizational membership expansion.
Representatives of each company spoke on the suggestions and expectations of the construction of professional committees. Zhang Hanchang took the lead in putting forward constructive proposals, hoping that the special committee would provide a dialogue channel between regulators and enterprises, and effectively convey the requirements of regulators and enterprises. At the same time, it is hoped that the special committee can build a resource sharing platform for enterprises, so as to transmit information more accurately and efficiently, provide a good platform atmosphere for exchanges and cooperation between enterprises, and provide support and assistance for the work of various enterprises.
Talking about the background, course and characteristics of the establishment of the special committee, Wang Xuegong gave a detailed account. He said that the establishment of the MAH Service and Collaboration Professional Committee is an important practice of the China Pharmaceutical Enterprise Management Association to better serve enterprises and promote the development of the industry, aiming to build a MAH industry ecology through professional services and communication and collaboration, integrating high-quality resources in the industry, so as to broaden the new development space around new formats, new ideas and new models. At the same time, it is necessary to find out the latest policy implementation progress, regional differences and other specific conditions, form a special report, communicate and report to the regulatory authorities, strive for support and resources, and improve brand appeal; To carry out activities such as annual forums, the topic setting should be clearer and clearer; It is necessary to fully do a good job in the preliminary work, solidly promote the development of the industry, and ensure that products, especially new products, meet clinical needs and benefit patients as soon as possible.
Before the start of the meeting, the China Pharmaceutical Enterprise Management Association visited the high-tech exhibition hall and anti-tumor lyophilized preparation workshop of Qilu Pharmaceutical Group, and after specifically understanding the development history, industrial layout, industry status, internationalization strategy, corporate culture construction and intelligent production of Qilu Pharmaceutical Group, praised its strong scientific and technological innovation strength and solid measures and results in protecting public health.
Relying on the strong strength of scientific and technological innovation, Qilu Pharmaceutical Group continues to contribute to the development of the pharmaceutical industry, always adheres to the principle of "doing scientific and technological innovation with temperature", and implements a series of measures in protecting public health, thus forming a unique corporate culture with Qilu characteristics and demonstrating the development and take-off of Chinese medicine.